Revvity Launches AI-Driven Drug Discovery Platforms at SLAS2026
Event summary
- Revvity introduced three new high-throughput drug discovery platforms at SLAS2026: Opera Phenix OptIQ, EnVision Nexus One, and AssayMate workstation.
- Opera Phenix OptIQ features 95% camera quantum efficiency and Phenologic.AI for advanced cellular analysis.
- EnVision Nexus One offers single-detector configuration for high-throughput screening with 21 CFR Part 11 compliance.
- AssayMate workstation provides intelligent automation with a fixed 8-channel head and drag-and-drop AssayPREP software.
The big picture
Revvity's new platforms reflect the growing trend of AI and automation in drug discovery, aiming to reduce bottlenecks and improve data quality. The company's focus on integrated workflow solutions aligns with the industry's shift towards high-throughput, data-driven approaches. With a strong presence in the S&P 500 and global reach, Revvity is positioning itself as a key player in the evolving landscape of health science solutions.
What we're watching
- Adoption Pace
- How quickly pharmaceutical and biotech labs will integrate these platforms into their workflows.
- Competitive Response
- Whether competitors will accelerate their own AI-driven drug discovery solutions.
- Revenue Impact
- The contribution of these new platforms to Revvity's $2.9 billion revenue.
Related topics